Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKCA NASDAQ:ALDR NASDAQ:ESPR NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/AESPREsperion Therapeutics$2.72-1.8%$1.92$0.69▼$3.94$558.49M0.895.88 million shs4.92 million shsLGNDLigand Pharmaceuticals$165.41-0.5%$149.01$93.58▼$169.49$3.26B0.96175,687 shs368,935 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics-1.81%+4.62%+29.52%+147.27%+52.81%LGNDLigand Pharmaceuticals-0.50%-0.34%+7.93%+44.29%+58.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/AALDRAlder Biopharmaceuticals$18.88$18.88$8.39▼$19.12$1.58B2.645.12 million shsN/AESPREsperion Therapeutics$2.72-1.8%$1.92$0.69▼$3.94$558.49M0.895.88 million shs4.92 million shsLGNDLigand Pharmaceuticals$165.41-0.5%$149.01$93.58▼$169.49$3.26B0.96175,687 shs368,935 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%ALDRAlder Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%ESPREsperion Therapeutics-1.81%+4.62%+29.52%+147.27%+52.81%LGNDLigand Pharmaceuticals-0.50%-0.34%+7.93%+44.29%+58.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea Therapeutics 0.00N/AN/AN/AALDRAlder Biopharmaceuticals 0.00N/AN/AN/AESPREsperion Therapeutics 2.80Moderate Buy$7.00157.35% UpsideLGNDLigand Pharmaceuticals 3.00Buy$176.506.70% UpsideCurrent Analyst Ratings BreakdownLatest LGND, ALDR, AKCA, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $175.008/28/2025LGNDLigand PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$157.00 ➝ $206.008/8/2025LGNDLigand PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$155.00 ➝ $185.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$145.00 ➝ $162.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14ALDRAlder Biopharmaceuticals$1.62M977.10N/AN/A$1.61 per share11.73ESPREsperion Therapeutics$332.31M1.65$0.02 per share115.29($1.97) per share-1.38LGNDLigand Pharmaceuticals$187.58M17.28$1.60 per share103.46$43.95 per share3.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/AALDRAlder Biopharmaceuticals-$296.43M-$4.87N/AN/AN/AN/A-226.13%-66.86%N/AESPREsperion Therapeutics-$51.74M-$0.49N/AN/A62.22-35.84%-0.91%-28.41%11/6/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A44.58N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)Latest LGND, ALDR, AKCA, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AALDRAlder BiopharmaceuticalsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78ALDRAlder Biopharmaceuticals1.748.948.94ESPREsperion TherapeuticsN/A1.150.76LGNDLigand PharmaceuticalsN/A5.455.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%ALDRAlder BiopharmaceuticalsN/AESPREsperion Therapeutics47.39%LGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%ALDRAlder Biopharmaceuticals15.40%ESPREsperion Therapeutics1.70%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableALDRAlder Biopharmaceuticals20283.84 millionN/AOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableLGND, ALDR, AKCA, and ESPR HeadlinesRecent News About These CompaniesLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Buy" by Analysts2 hours ago | marketbeat.comLigand Pharma Amends Credit Agreement for StabilitySeptember 16 at 5:50 PM | tipranks.comRhumbline Advisers Sells 1,989 Shares of Ligand Pharmaceuticals Incorporated $LGNDSeptember 15 at 4:59 AM | marketbeat.comEllsworth Advisors LLC Makes New Investment in Ligand Pharmaceuticals Incorporated $LGNDSeptember 13, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Sees Large Growth in Short InterestSeptember 11, 2025 | marketbeat.comBaird Financial Group Inc. Reduces Stock Position in Ligand Pharmaceuticals Incorporated $LGNDSeptember 10, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Invests $16.53 Million in Ligand Pharmaceuticals Incorporated $LGNDSeptember 9, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Bought by Clark Capital Management Group Inc.September 7, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $190.00 at OppenheimerSeptember 5, 2025 | marketbeat.comInsider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of StockSeptember 5, 2025 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High After Analyst UpgradeSeptember 5, 2025 | marketbeat.comBenchmark Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) StockSeptember 4, 2025 | marketbeat.comWhat Analysts Are Saying About Ligand Pharmaceuticals StockSeptember 3, 2025 | benzinga.comLigand Pharmaceuticals Incorporated $LGND Stake Reduced by Ashford Capital Management Inc.September 1, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Acquired by Northern Trust CorpSeptember 1, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Purchased by American Century Companies Inc.September 1, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High Following Analyst UpgradeAugust 31, 2025 | marketbeat.comNuveen LLC Buys New Stake in Ligand Pharmaceuticals Incorporated $LGNDAugust 29, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Buy" from BrokeragesAugust 26, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Bought by CW Advisors LLCAugust 24, 2025 | marketbeat.comInvesco Ltd. Purchases 8,473 Shares of Ligand Pharmaceuticals Incorporated $LGNDAugust 23, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGND, ALDR, AKCA, and ESPR Company DescriptionsAkcea Therapeutics NASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Alder Biopharmaceuticals NASDAQ:ALDRAlder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Esperion Therapeutics NASDAQ:ESPR$2.72 -0.05 (-1.81%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$2.77 +0.05 (+1.80%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Ligand Pharmaceuticals NASDAQ:LGND$165.41 -0.83 (-0.50%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$165.50 +0.09 (+0.05%) As of 09/17/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
